

# Dai Horiuchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4014575/publications.pdf>

Version: 2024-02-01

7  
papers

636  
citations

1307594

7  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

1661  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. <i>Cell Chemical Biology</i> , 2022, 29, 358-372.e5.	5.2	10
2	Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17543-17550.	7.1	54
3	NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity. <i>Free Radical Biology and Medicine</i> , 2018, 126, 358-371.	2.9	12
4	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. <i>Nature Medicine</i> , 2016, 22, 1321-1329.	30.7	138
5	Taking on Challenging Targets: Making MYC Druggable. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e497-e502.	3.8	49
6	Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1019-27.	7.1	64
7	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. <i>Journal of Experimental Medicine</i> , 2012, 209, 679-696.	8.5	309